Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Destabilization of AETFC through C/EBPα-mediated repression of LYL1 contributes to t(8;21) leukemic cell differentiation.

Zhang MM, Liu N, Zhang YL, Rong B, Wang XL, Xu CH, Xie YY, Shen S, Zhu J, Nimer SD, Chen Z, Chen SJ, Roeder RG, Lan F, Wang L, Huang QH, Sun XJ.

Leukemia. 2019 Jul;33(7):1822-1827. doi: 10.1038/s41375-019-0398-8. Epub 2019 Feb 12. No abstract available.

PMID:
30755707
2.

ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.

Guo Y, Zhou Y, Yamatomo S, Yang H, Zhang P, Chen S, Nimer SD, Zhao ZJ, Xu M, Bai J, Yang FC.

Leukemia. 2019 May;33(5):1287-1291. doi: 10.1038/s41375-018-0347-y. Epub 2019 Jan 16. No abstract available.

PMID:
30651633
3.

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.

Greenblatt SM, Man N, Hamard PJ, Asai T, Karl D, Martinez C, Bilbao D, Stathias V, Jermakowicz AM, Duffort S, Tadi M, Blumenthal E, Newman S, Vu L, Xu Y, Liu F, Schurer SC, McCabe MT, Kruger RG, Xu M, Yang FC, Tenen DG, Watts J, Vega F, Nimer SD.

Cancer Cell. 2019 Jan 14;35(1):156. doi: 10.1016/j.ccell.2018.12.008. No abstract available.

PMID:
30645972
4.

Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.

Liu N, Song J, Xie Y, Wang XL, Rong B, Man N, Zhang MM, Zhang Q, Gao FF, Du MR, Zhang Y, Shen J, Xu CH, Hu CL, Wu JC, Liu P, Zhang YL, Xie YY, Liu P, Huang JY, Huang QH, Lan F, Shen S, Nimer SD, Chen Z, Chen SJ, Roeder RG, Wang L, Sun XJ.

Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):890-899. doi: 10.1073/pnas.1809327116. Epub 2018 Dec 28.

5.

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.

Greenblatt SM, Man N, Hamard PJ, Asai T, Karl D, Martinez C, Bilbao D, Stathias V, McGrew-Jermacowicz A, Duffort S, Tadi M, Blumenthal E, Newman S, Vu L, Xu Y, Liu F, Schurer SC, McCabe MT, Kruger RG, Xu M, Yang FC, Tenen D, Watts J, Vega F, Nimer SD.

Cancer Cell. 2018 Nov 12;34(5):868. doi: 10.1016/j.ccell.2018.10.009. No abstract available.

6.

Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.

Zhang P, He F, Bai J, Yamamoto S, Chen S, Zhang L, Sheng M, Zhang L, Guo Y, Man N, Yang H, Wang S, Cheng T, Nimer SD, Zhou Y, Xu M, Wang QF, Yang FC.

J Clin Invest. 2018 Dec 3;128(12):5383-5398. doi: 10.1172/JCI121366. Epub 2018 Oct 29.

7.

PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.

Hamard PJ, Santiago GE, Liu F, Karl DL, Martinez C, Man N, Mookhtiar AK, Duffort S, Greenblatt S, Verdun RE, Nimer SD.

Cell Rep. 2018 Sep 4;24(10):2643-2657. doi: 10.1016/j.celrep.2018.08.002.

8.

Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes.

Hayashi Y, Zhang Y, Yokota A, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger GM, Wang J, Dong Y, Zhou Y, Wang J, Wu L, Bu J, Chen A, Zhao X, Sun X, Chetal K, Olsson A, Watanabe M, Romick-Rosendale LE, Harada H, Shih LY, Tse W, Bridges JP, Caligiuri MA, Huang T, Zheng Y, Witte DP, Wang QF, Qu CK, Salomonis N, Grimes HL, Nimer SD, Xiao Z, Huang G.

Cancer Discov. 2018 Nov;8(11):1438-1457. doi: 10.1158/2159-8290.CD-17-1203. Epub 2018 Aug 23.

PMID:
30139811
9.

p300 suppresses leukemia development in NUP98-HOXD13 driven myelodysplastic syndrome.

Man N, Nimer SD.

Oncotarget. 2018 Jun 1;9(42):26603-26604. doi: 10.18632/oncotarget.23402. eCollection 2018 Jun 1. No abstract available.

10.

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.

Greenblatt SM, Man N, Hamard PJ, Asai T, Karl D, Martinez C, Bilbao D, Stathias V, Jermakowicz AM, Duffort S, Tadi M, Blumenthal E, Newman S, Vu L, Xu Y, Liu F, Schurer SC, McCabe MT, Kruger RG, Xu M, Yang FC, Tenen DG, Watts J, Vega F, Nimer SD.

Cancer Cell. 2018 Jun 11;33(6):1111-1127.e5. doi: 10.1016/j.ccell.2018.05.007. Erratum in: Cancer Cell. 2018 Nov 12;34(5):868. Cancer Cell. 2019 Jan 14;35(1):156.

11.

CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.

Luo H, Wang F, Zha J, Li H, Yan B, Du Q, Yang F, Sobh A, Vulpe C, Drusbosky L, Cogle C, Chepelev I, Xu B, Nimer SD, Licht J, Qiu Y, Chen B, Xu M, Huang S.

Blood. 2018 Aug 23;132(8):837-848. doi: 10.1182/blood-2017-11-814319. Epub 2018 May 14.

12.

Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.

Guo Y, Yang H, Chen S, Zhang P, Li R, Nimer SD, Harbour JW, Xu M, Yang FC.

Leukemia. 2018 Aug;32(8):1834-1837. doi: 10.1038/s41375-018-0126-9. Epub 2018 Apr 2. No abstract available.

13.

Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.

Yang H, Kurtenbach S, Guo Y, Lohse I, Durante MA, Li J, Li Z, Al-Ali H, Li L, Chen Z, Field MG, Zhang P, Chen S, Yamamoto S, Li Z, Zhou Y, Nimer SD, Harbour JW, Wahlestedt C, Xu M, Yang FC.

Blood. 2018 Jan 18;131(3):328-341. doi: 10.1182/blood-2017-06-789669. Epub 2017 Nov 7.

14.

Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.

Kaushik S, Liu F, Veazey KJ, Gao G, Das P, Neves LF, Lin K, Zhong Y, Lu Y, Giuliani V, Bedford MT, Nimer SD, Santos MA.

Leukemia. 2018 Feb;32(2):499-509. doi: 10.1038/leu.2017.206. Epub 2017 Jun 30.

15.

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.

J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.

16.

Loss of Asxl2 leads to myeloid malignancies in mice.

Li J, He F, Zhang P, Chen S, Shi H, Sun Y, Guo Y, Yang H, Man N, Greenblatt S, Li Z, Guo Z, Zhou Y, Wang L, Morey L, Williams S, Chen X, Wang QT, Nimer SD, Yu P, Wang QF, Xu M, Yang FC.

Nat Commun. 2017 Jun 8;8:15456. doi: 10.1038/ncomms15456.

17.

Histone-binding of DPF2 mediates its repressive role in myeloid differentiation.

Huber FM, Greenblatt SM, Davenport AM, Martinez C, Xu Y, Vu LP, Nimer SD, Hoelz A.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6016-6021. doi: 10.1073/pnas.1700328114. Epub 2017 May 22.

18.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.

Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.

19.

Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.

Man N, Tan Y, Sun XJ, Liu F, Cheng G, Greenblatt SM, Martinez C, Karl DL, Ando K, Sun M, Hou D, Chen B, Xu M, Yang FC, Chen Z, Chen S, Nimer SD, Wang L.

Blood. 2017 May 18;129(20):2782-2792. doi: 10.1182/blood-2016-10-745034. Epub 2017 Apr 5.

20.

Covalent Modifications of RUNX Proteins: Structure Affects Function.

Blumenthal E, Greenblatt S, Huang G, Ando K, Xu Y, Nimer SD.

Adv Exp Med Biol. 2017;962:33-44. doi: 10.1007/978-981-10-3233-2_3. Review.

PMID:
28299649
21.

ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis.

Li Z, Zhang P, Yan A, Guo Z, Ban Y, Li J, Chen S, Yang H, He Y, Li J, Guo Y, Zhang W, Hajiramezanali E, An H, Fajardo D, Harbour JW, Ruan Y, Nimer SD, Yu P, Chen X, Xu M, Yang FC.

Sci Adv. 2017 Jan 20;3(1):e1601602. doi: 10.1126/sciadv.1601602. eCollection 2017 Jan.

22.

Loss of p300 accelerates MDS-associated leukemogenesis.

Cheng G, Liu F, Asai T, Lai F, Man N, Xu H, Chen S, Greenblatt S, Hamard PJ, Ando K, Chen X, Wang L, Martinez C, Tadi M, Wang L, Xu M, Yang FC, Shiekhattar R, Nimer SD.

Leukemia. 2017 Jun;31(6):1382-1390. doi: 10.1038/leu.2016.347. Epub 2016 Nov 24.

23.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

24.

Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape.

Liu F, Wang L, Perna F, Nimer SD.

Nat Rev Cancer. 2016 Jun;16(6):359-72. doi: 10.1038/nrc.2016.41. Review.

25.

Arginine methyltransferases in normal and malignant hematopoiesis.

Greenblatt SM, Liu F, Nimer SD.

Exp Hematol. 2016 Jun;44(6):435-41. doi: 10.1016/j.exphem.2016.03.009. Epub 2016 Mar 26. Review.

26.

Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms.

Asai T, Hatlen MA, Lossos C, Ndiaye-Lobry D, Deblasio A, Murata K, Fleisher M, Cortizas EM, Verdun RE, Petrini J, Nimer SD.

Sci Rep. 2016 Mar 10;6:22760. doi: 10.1038/srep22760.

27.

Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin.

Man N, Sun XJ, Tan Y, García-Cao M, Liu F, Cheng G, Hatlen M, Xu H, Shah R, Chastain N, Liu N, Huang G, Zhou Y, Sheng M, Song J, Yang FC, Benezra R, Nimer SD, Wang L.

Blood. 2016 May 12;127(19):2322-6. doi: 10.1182/blood-2015-11-677708. Epub 2016 Mar 4.

28.

Mutational Landscape and Antiproliferative Functions of ELF Transcription Factors in Human Cancer.

Ando M, Kawazu M, Ueno T, Koinuma D, Ando K, Koya J, Kataoka K, Yasuda T, Yamaguchi H, Fukumura K, Yamato A, Soda M, Sai E, Yamashita Y, Asakage T, Miyazaki Y, Kurokawa M, Miyazono K, Nimer SD, Yamasoba T, Mano H.

Cancer Res. 2016 Apr 1;76(7):1814-24. doi: 10.1158/0008-5472.CAN-14-3816. Epub 2016 Feb 26.

29.

MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.

Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ, Verma A, Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG.

Nat Commun. 2016 Feb 22;7:10739. doi: 10.1038/ncomms10739.

30.

Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles.

Hatlen MA, Arora K, Vacic V, Grabowska EA, Liao W, Riley-Gillis B, Oschwald DM, Wang L, Joergens JE, Shih AH, Rapaport F, Gu S, Voza F, Asai T, Neel BG, Kharas MG, Gonen M, Levine RL, Nimer SD.

J Exp Med. 2016 Jan 11;213(1):25-34. doi: 10.1084/jem.20150524. Epub 2015 Dec 14.

31.

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A.

Leukemia. 2015 Dec;29(12):2452. doi: 10.1038/leu.2015.312. No abstract available.

PMID:
26648407
32.

PARP inhibitors: a treatment option for AML?

Wang L, Hamard PJ, Nimer SD.

Nat Med. 2015 Dec;21(12):1393-4. doi: 10.1038/nm.4007. No abstract available.

PMID:
26646494
33.

A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species.

Zong H, Gozman A, Caldas-Lopes E, Taldone T, Sturgill E, Brennan S, Ochiana SO, Gomes-DaGama EM, Sen S, Rodina A, Koren J 3rd, Becker MW, Rudin CM, Melnick A, Levine RL, Roboz GJ, Nimer SD, Chiosis G, Guzman ML.

Cell Rep. 2015 Dec 15;13(10):2159-73. doi: 10.1016/j.celrep.2015.10.073. Epub 2015 Nov 25.

34.

Combined Loss of Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in Mice.

Zhao Z, Chen L, Dawlaty MM, Pan F, Weeks O, Zhou Y, Cao Z, Shi H, Wang J, Lin L, Chen S, Yuan W, Qin Z, Ni H, Nimer SD, Yang FC, Jaenisch R, Jin P, Xu M.

Cell Rep. 2015 Nov 24;13(8):1692-704. doi: 10.1016/j.celrep.2015.10.037. Epub 2015 Nov 12.

35.

Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis.

Liu F, Cheng G, Hamard PJ, Greenblatt S, Wang L, Man N, Perna F, Xu H, Tadi M, Luciani L, Nimer SD.

J Clin Invest. 2015 Sep;125(9):3532-44. doi: 10.1172/JCI81749. Epub 2015 Aug 10.

36.

Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression.

Wang L, Man N, Sun XJ, Tan Y, García-Cao M, Liu F, Hatlen M, Xu H, Huang G, Mattlin M, Mehta A, Rampersaud E, Benezra R, Nimer SD.

Blood. 2015 Jul 30;126(5):640-50. doi: 10.1182/blood-2015-03-635532. Epub 2015 Jun 17. Erratum in: Blood. 2016 Apr 14;127(15):1941. Cao, Marta Garcia [corrected to Garcia-Cao, Marta]. Blood. 2016 Sep 29;128(13):1778. Blood. 2016 Apr 14;127(15):1941.

37.

The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis.

Sun XJ, Man N, Tan Y, Nimer SD, Wang L.

Front Oncol. 2015 May 26;5:108. doi: 10.3389/fonc.2015.00108. eCollection 2015. Review.

38.

Loss of RUNX1/AML1 arginine-methylation impairs peripheral T cell homeostasis.

Mizutani S, Yoshida T, Zhao X, Nimer SD, Taniwaki M, Okuda T.

Br J Haematol. 2015 Sep;170(6):859-73. doi: 10.1111/bjh.13499. Epub 2015 May 26.

39.

Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, Woods B, Wei C, Hatlen M, Baljevic M, Nimer SD, Tallman M, Paietta E, Cimmino L, Aifantis I, Steidl U, Mason C, Melnick A, Levine RL.

Cancer Cell. 2015 Apr 13;27(4):502-15. doi: 10.1016/j.ccell.2015.03.009.

40.

Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells.

Kotini AG, Chang CJ, Boussaad I, Delrow JJ, Dolezal EK, Nagulapally AB, Perna F, Fishbein GA, Klimek VM, Hawkins RD, Huangfu D, Murry CE, Graubert T, Nimer SD, Papapetrou EP.

Nat Biotechnol. 2015 Jun;33(6):646-55. doi: 10.1038/nbt.3178. Epub 2015 Mar 23.

41.

The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells.

Perna F, Vu LP, Themeli M, Kriks S, Hoya-Arias R, Khanin R, Hricik T, Mansilla-Soto J, Papapetrou EP, Levine RL, Studer L, Sadelain M, Nimer SD.

Stem Cell Reports. 2015 Apr 14;4(4):658-69. doi: 10.1016/j.stemcr.2015.02.003. Epub 2015 Mar 5.

42.

Chromatin modifiers and the promise of epigenetic therapy in acute leukemia.

Greenblatt SM, Nimer SD.

Leukemia. 2014 Jul;28(7):1396-406. doi: 10.1038/leu.2014.94. Epub 2014 Mar 10. Review.

43.

Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal.

Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, Tse W, Tenen DG, Wang Q, Chen W, Mulloy JC, Nimer SD, Huang G.

Blood. 2014 Mar 13;123(11):1729-38. doi: 10.1182/blood-2013-03-489575. Epub 2014 Jan 21.

44.

PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex.

Vu LP, Perna F, Wang L, Voza F, Figueroa ME, Tempst P, Erdjument-Bromage H, Gao R, Chen S, Paietta E, Deblasio T, Melnick A, Liu Y, Zhao X, Nimer SD.

Cell Rep. 2013 Dec 26;5(6):1625-38. doi: 10.1016/j.celrep.2013.11.025. Epub 2013 Dec 12.

45.

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A; MDS-003 Study Investigators.

Leukemia. 2014 May;28(5):1033-40. doi: 10.1038/leu.2013.305. Epub 2013 Oct 22. Erratum in: Leukemia. 2015 Dec;29(12):2452.

46.

Necdin, a p53 target gene, in stem cells.

Asai T, Liu Y, Nimer SD.

Oncotarget. 2013 Jun;4(6):806-7. No abstract available.

47.

A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.

Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, Chen WY, Tang Z, Nakadai T, Elemento O, Fischle W, Melnick A, Patel DJ, Nimer SD, Roeder RG.

Nature. 2013 Aug 1;500(7460):93-7. doi: 10.1038/nature12287. Epub 2013 Jun 30.

48.

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.

Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, Nimer SD, Levine RL, Klimek VM.

Haematologica. 2013 Jun;98(6):908-12. doi: 10.3324/haematol.2012.076729. Epub 2013 Jan 24.

49.

Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential.

Vu LP, Luciani L, Nimer SD.

Int J Hematol. 2013 Feb;97(2):198-209. doi: 10.1007/s12185-012-1247-y. Epub 2013 Jan 4. Review.

50.

PI3K-Akt pathway regulates polycomb group protein and stem cell maintenance.

Liu Y, Yu H, Nimer SD.

Cell Cycle. 2013 Jan 15;12(2):199-200. doi: 10.4161/cc.23379. Epub 2012 Jan 15. No abstract available.

Supplemental Content

Loading ...
Support Center